替格瑞洛在经皮冠状动脉介入治疗术后患者中的应用：一家社区医院的一年随访
Ticagrelor use in patients after percutaneous coronary intervention: one year follow up in a community hospital.
作者信息
Mannumbeth Renjithlal Sarath Lal, Magdi Mohamed, Renjith Keerthi, Mostafa Mostafa Reda, Syed Musaib, Shaukat Fahd, Zahid Viqarunnisa, Ritter Nathan
机构信息
Internal Medicine Residency Program, Unity Hospital, Rochester Regional Health Rochester, NY, USA.
K S Hegde Medical Academy India.
出版信息
Am J Cardiovasc Dis. 2022 Jun 15;12(3):143-148. eCollection 2022.
BACKGROUND
Current guidelines from American College of Cardiology (ACC) recommend ticagrelor over clopidogrel in patients with acute coronary syndrome. We have observed many patients being switched from ticagrelor to clopidogrel after percutaneous coronary intervention (PCI) in our hospital. Our goal is to evaluate the use rate of ticagrelor and categorize the reasons for non-use.
METHODS
We performed a retrospective data analysis of all patients who underwent PCI at Unity Hospital of Rochester, New York, from January 2019 to January 2020. A total of 330 patients underwent PCI for ACS over the year. After exclusions, 277 patients were enrolled in the analysis.
RESULTS
Of the 277 patients, 179 (65%) completed one year of ticagrelor therapy, and 98 (35%) stopped ticagrelor and transitioned to clopidogrel. The most common reason for switching from ticagrelor was dyspnea (42 patients), followed by cost concerns (41 patients).
CONCLUSION
At our community hospital, completion of one-year use of ticagrelor post-PCI occurred in 65% of patients. The most common reasons for discontinuation are dyspnea and medication cost.
背景
美国心脏病学会（ACC）目前的指南推荐在急性冠状动脉综合征患者中使用替格瑞洛而非氯吡格雷。在我们医院，我们观察到许多患者在经皮冠状动脉介入治疗（PCI）后从替格瑞洛转换为氯吡格雷。我们的目标是评估替格瑞洛的使用率并对未使用的原因进行分类。
方法
我们对2019年1月至2020年1月在纽约罗切斯特团结医院接受PCI的所有患者进行了回顾性数据分析。全年共有330例患者因急性冠状动脉综合征接受了PCI。排除后，277例患者纳入分析。
结果
在277例患者中，179例（65%）完成了一年的替格瑞洛治疗，98例（35%）停止使用替格瑞洛并转换为氯吡格雷。从替格瑞洛转换的最常见原因是呼吸困难（42例患者），其次是费用担忧（41例患者）。
结论
在我们的社区医院，65%的患者在PCI后完成了一年的替格瑞洛使用。停药的最常见原因是呼吸困难和药物费用。
Zotero 插件